ClinicalTrials.gg
CompletedNCT02564926BEYONDUpdated Aug 20, 2019Results posted

Foxiga Korea Local Phase 4 Study

A Phase 4 interventional study of Dapagliflozin and Glimepiride in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed at 14 sites in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
76th of 180
125 · median 82
Started
2016
with 18 others
Phase 4
77 of 180
7 open now
Registered
69th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 76th largest by enrollment, is one of 19 that started in 2016, is one of 77 in phase 4, and was the 69th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.

Read the detailed description

This is a 52 weeks, randomized, open-label, parallel-group, multi-centres phase IV study.

Participants will be randomized 1:1 to receive dapagliflozin 10 mg qd or glimepiride 1\~2 mgqd in an open-label manner for 12 months as add-on to metformin 1000 mg.

Parallel group study design was chosen. In order maintain the practicality of the phase IV study, open label design of study drug delivery was chosen. The reading of the DXA scans will be conducted by one expert in blinded manner. Glimepiride is the most frequently used SUs in Korea and therefore this was chosen as comparator.Dapagliflozin treatment will be associated with reduction of total body FM, BW, abdominal VAT and SAT volume compared with glimepiride.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • DM
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults with T2DM (Male or female, ≥ 19 and ≤ 75 yrs)
  2. Patients in insufficient glycemic control ( > 7.5% and \< 9.5% in recent 4 weeks)
  3. Patients with an unchanged dose of metformin (≥ 1,000 mg/day) for > 8 weeks prior to randomization
  4. Written
  5. must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose.

    • WOCBP must have a negative urine pregnancy test at screening visit WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not .
    • WOCBP must be willing to use a medically accepted method of that is considered reliable in the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes or history of diabetic ketoacidosis
  2. Pregnant or breast-feeding patients
  3. \< 60 mL/min/1.73 m2 (MDRD) on visit 1.
  4. Indication of active liver disease (/ALT/total > 3 X ) on visit 1.
  5. Acute coronary syndrome, stroke or within 3 months prior to randomization
  6. Bariatric surgery within 2 years; treatment of anti-obesity drugs 3 months prior to randomization; any treatment leading to unstable body weight. (Unstable body weight is considered reliable in the judgment of the Investigator.)
  7. History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
  8. History of any other within 5 years (with the exception of successfully treated non-melanoma skin cancers)
  9. History of alcohol or drug abuse judged by physician within 3 months prior to randomization
  10. Concomitant participation in any other clinical study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Dapagliflozin 10mg + Metformin 1000mg

    Drug: Dapagliflozin

  • Active comparator
    Glimepiride

    Glimepiriide 1-2mg + Metformin 1000mg

    Drug: Glimepiride

Interventions

  • Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment

  • Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan

    Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment

    Time frame: From baseline to Week 52

  2. Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan

    Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Adjusted Mean Change in HbA1c at Week 52

    Adjusted Mean Change in HbA1c at Week 52

    Time frame: From baseline to Week 52

  2. HbA1c <7.0% at Week 52

    HbA1c \<7.0% at Week 52

    Time frame: 52 weeks

  3. Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52

    Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52

    Time frame: From baseline to Week 52

  4. Adjusted Mean Change in Total Body Weight at Week 52

    Adjusted Mean Change in Total Body Weight at Week 52

    Time frame: From baseline to Week 52

  5. Adjusted Mean Change in Waist Circumference at Week 52

    Adjusted Mean Change in Waist Circumference at Week 52

    Time frame: From baseline to Week 52

  6. Adjusted Mean Change in Body Mass Index (BMI) at Week 52

    Adjusted Mean Change in Body Mass Index (BMI) at Week 52

    Time frame: From baseline to Week 52

  7. Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52

    Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52

    Time frame: From baseline to Week 52

  8. Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52

    Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52

    Time frame: From baseline to Week 52

  9. Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52

    Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52

    Time frame: From baseline to Week 52

  10. Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52

    Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52

    Time frame: From baseline to Week 52

  11. Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52

    Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52

    Time frame: From baseline to Week 52

  12. Adjusted Mean Change in Lean Body Mass at Week 52

    Adjusted Mean Change in Lean Body Mass at Week 52

    Time frame: From baseline to Week 52

  13. Adjusted Mean Change in Adinopectin at Week 52

    Adjusted Mean Change in Adinopectin at Week 52

    Time frame: From baseline to Week 52

  14. Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52

    Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52

    Time frame: From baseline to Week 52

07

Results

Posted Aug 20, 2019

Participant flow

First patient enrolled: 05 January 2016 Last patient last visit: 15 January 2018

Participant flow — Overall Study
MilestoneDapagliflozinGlimepiride
Started6061
Completed5254
Not completed87

Outcome measures

PrimaryAdjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan

Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · grams
Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan
gramsDapagliflozinGlimepiride
Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan-1485.69 (-2025.543 to -945.844)1096.34 (556.489 to 1636.187)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = <0.001 · Ls mean difference (kg): -2.6 · 95% CI -3.346 to -1.819
SecondaryAdjusted Mean Change in HbA1c at Week 52

Adjusted Mean Change in HbA1c at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · percentages
Adjusted Mean Change in HbA1c at Week 52
percentagesDapagliflozinGlimepiride
Adjusted Mean Change in HbA1c at Week 52-1.00 (-1.259 to -0.745)-0.54 (-0.802 to -0.287)
Statistical analysis
  • Dapagliflozin vs Glimepiride · Mixed Models Analysis · p = 0.014 · Ls mean difference (%): -0.46 · 95% CI -0.821 to -0.094
SecondaryHbA1c <7.0% at Week 52

HbA1c \<7.0% at Week 52

Time frame:
52 weeks
Reported as:
Count of participants · Participants
HbA1c <7.0% at Week 52
ParticipantsDapagliflozinGlimepiride
Count of participants that achieved the response2722
Statistical analysis
  • Dapagliflozin vs Glimepiride · Regression, Logistic · p = 0.343 · Odds ratio (or): 1.45 · 95% CI 0.673 to 3.113
SecondaryAdjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52

Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · mg/dL
Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52
mg/dLDapagliflozinGlimepiride
Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52-30.94 (-40.084 to -21.800)-12.70 (-21.786 to -3.607)
Statistical analysis
  • Dapagliflozin vs Glimepiride · Mixed Models Analysis · p = 0.006 · Ls mean difference (mg/dl): -18.25 · 95% CI -31.140 to -5.351
SecondaryAdjusted Mean Change in Total Body Weight at Week 52

Adjusted Mean Change in Total Body Weight at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · kg
Adjusted Mean Change in Total Body Weight at Week 52
kgDapagliflozinGlimepiride
Adjusted Mean Change in Total Body Weight at Week 52-2.4 (-3.104 to -1.664)1.3 (0.545 to 1.984)
Statistical analysis
  • Dapagliflozin vs Glimepiride · Mixed Models Analysis · p = <0.001 · Ls mean difference (kg): -3.7 · 95% CI -4.667 to -2.631
SecondaryAdjusted Mean Change in Waist Circumference at Week 52

Adjusted Mean Change in Waist Circumference at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · cm
Adjusted Mean Change in Waist Circumference at Week 52
cmDapagliflozinGlimepiride
Adjusted Mean Change in Waist Circumference at Week 52-2.37 (-3.480 to -1.253)-0.16 (-1.271 to 0.957)
Statistical analysis
  • Dapagliflozin vs Glimepiride · Mixed Models Analysis · p = 0.006 · Ls mean difference (cm): -2.21 · 95% CI -3.785 to -0.635
SecondaryAdjusted Mean Change in Body Mass Index (BMI) at Week 52

Adjusted Mean Change in Body Mass Index (BMI) at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · kg/m^2
Adjusted Mean Change in Body Mass Index (BMI) at Week 52
kg/m^2DapagliflozinGlimepiride
Adjusted Mean Change in Body Mass Index (BMI) at Week 52-0.91 (-1.172 to -0.640)0.46 (0.194 to 0.726)
Statistical analysis
  • Dapagliflozin vs Glimepiride · Mixed Models Analysis · p = <0.001 · Ls mean difference (kg/m2): -1.37 · 95% CI -1.742 to -0.990
SecondaryAdjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52

Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · mmHg
Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52
mmHgDapagliflozinGlimepiride
Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52-2.18 (-5.123 to 0.766)4.63 (1.682 to 7.570)
Statistical analysis
  • Dapagliflozin vs Glimepiride · Mixed Models Analysis · p = 0.002 · Ls mean difference (mmhg): -6.81 · 95% CI -10.969 to -2.641
SecondaryAdjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52

Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · mmHg
Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52
mmHgDapagliflozinGlimepiride
Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52-0.25 (-2.523 to 2.023)2.36 (0.092 to 4.638)
Statistical analysis
  • Dapagliflozin vs Glimepiride · Mixed Models Analysis · p = 0.110 · Ls mean difference (mmhg): -2.61 · 95% CI -5.829 to 0.600
SecondaryAdjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52

Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · cm^2
Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52
cm^2DapagliflozinGlimepiride
Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52-16.06 (-23.806 to -8.317)1.48 (-6.407 to 9.377)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = 0.002 · Ls mean difference (cm2): -17.55 · 95% CI -28.603 to -6.489
SecondaryAdjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52

Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · cm^2
Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52
cm^2DapagliflozinGlimepiride
Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52-5.41 (-11.804 to 0.994)12.98 (6.462 to 19.506)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = <0.001 · Ls mean difference (cm2): -18.39 · 95% CI -27.561 to -9.218
SecondaryAdjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52

Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · ratio
Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52
ratioDapagliflozinGlimepiride
Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52-0.05 (-0.115 to 0.017)-0.02 (-0.084 to 0.050)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = 0.503 · Ls mean difference: -0.03 · 95% CI -0.127 to 0.063
SecondaryAdjusted Mean Change in Lean Body Mass at Week 52

Adjusted Mean Change in Lean Body Mass at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · Kg
Adjusted Mean Change in Lean Body Mass at Week 52
KgDapagliflozinGlimepiride
Adjusted Mean Change in Lean Body Mass at Week 52-1.1 (-1.608 to -0.570)0.2 (-0.329 to 0.683)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = <0.001 · Ls mean difference: -1.3 · 95% CI -1.992 to -0.540
SecondaryAdjusted Mean Change in Adinopectin at Week 52

Adjusted Mean Change in Adinopectin at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · ng/mL
Adjusted Mean Change in Adinopectin at Week 52
ng/mLDapagliflozinGlimepiride
Adjusted Mean Change in Adinopectin at Week 521746.66 (1296.144 to 2197.181)1088.95 (638.431 to 1539.468)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = 0.044 · Ls mean difference (ng/ml): 657.71 · 95% CI 18.325 to 1297.101
SecondaryAdjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52

Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · mg/L
Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52
mg/LDapagliflozinGlimepiride
Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52-0.51 (-1.030 to 0.014)-0.39 (-0.914 to 0.131)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = 0.756 · Ls mean difference (mg/l): -0.12 · 95% CI -0.858 to 0.625
PrimaryAdjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan

Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · percent change
Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan
percent changeDapagliflozinGlimepiride
Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan-1.21 (-1.821 to -0.604)0.73 (0.123 to 1.341)
Statistical analysis
  • Dapagliflozin vs Glimepiride · ANCOVA · p = <0.001 · Ls mean difference (%): -1.94 · 95% CI -2.807 to -1.082

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin0/60 (0%)6/60 (10%)11/60 (18.3%)
Glimepiride0/61 (0%)6/61 (9.8%)10/61 (16.4%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDapagliflozinGlimepiride
Rib fractureInjury, poisoning and procedural complications1/600/61
Splenic injuryInjury, poisoning and procedural complications1/600/61
Subdural haemorrhageInjury, poisoning and procedural complications1/600/61
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/600/61
Transient ischaemic attackNervous system disorders1/600/61
Conversion disorderPsychiatric disorders1/600/61
Tibia fractureInjury, poisoning and procedural complications1/600/61
Pyelonephritis acuteInfections and infestations0/601/61
Ankle fractureInjury, poisoning and procedural complications0/601/61
Joint dislocationInjury, poisoning and procedural complications0/601/61
Most frequent other events
Most frequent other events
EventDapagliflozinGlimepiride
HypoglycaemiaMetabolism and nutrition disorders3/607/61
ToothacheGastrointestinal disorders4/601/61
NasopharyngitisInfections and infestations4/602/61

Baseline characteristics

Age, Continuous
Age, Continuous(years)DapagliflozinGlimepirideTotal
Mean54.6 ± 9.0955.7 ± 10.2455.2 ± 9.66
Sex: Female, Male
Sex: Female, Male(Participants)DapagliflozinGlimepirideTotal
Female233457
Male372764
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DapagliflozinGlimepirideTotal
Korean6061121
08

Study locations

14 sites
  • Research Site
    Ansan-si, 15355, Korea, Republic of
  • Research Site
    Changwon-si, 51353, Korea, Republic of
  • Research Site
    Daegu, 41931, Korea, Republic of
  • Research Site
    Daejeon-si, 35233, Korea, Republic of
  • Research Site
    Goyang-si, 10326, Korea, Republic of
  • Research Site
    Incheon, 21565, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 01830, Korea, Republic of
  • Research Site
    Seoul, 04401, Korea, Republic of
  • Research Site
    Seoul, 05278, Korea, Republic of
  • Research Site
    Seoul, 06273, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Uijeongbu-si, 11765, Korea, Republic of
  • Research Site
    Wonju-si, 220-701, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jan 2018, 24 months.

Results were first posted in Aug 2019, 1 year 7 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 24 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2015
First posted
Oct 1, 2015
StartActual
Jan 5, 2016
Primary completionActual
Jan 15, 2018
CompletionActual
Jan 15, 2018
Results first posted
Aug 20, 2019
Last update
Aug 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02564926
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Jan 5, 2016
Primary completion
Jan 15, 2018
Completion
Jan 15, 2018
Results posted
Aug 20, 2019
Last update
Aug 20, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion